Neuralstem (CUR) Earning Somewhat Positive Media Coverage, Study Shows
Media coverage about Neuralstem (NASDAQ:CUR) has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neuralstem earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.4349028940381 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Comparing Sophiris Bio (SPHS) & Neuralstem (CUR) (americanbankingnews.com)
- Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update – GlobeNewswire (press release) (globenewswire.com)
- Neuralstem : reports 3Q loss (4-traders.com)
- Neuralstem reports 3Q loss (finance.yahoo.com)
Separately, ValuEngine lowered Neuralstem from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th.
Neuralstem (NASDAQ:CUR) opened at $0.94 on Wednesday. Neuralstem has a fifty-two week low of $0.91 and a fifty-two week high of $6.60.
COPYRIGHT VIOLATION WARNING: “Neuralstem (CUR) Earning Somewhat Positive Media Coverage, Study Shows” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/neuralstem-cur-earning-somewhat-positive-media-coverage-study-shows/1703603.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.